Although this estimate is higher than the 15%–25% of familial risk attributed to all BRCA1 and BRCA2 mutations combined in non-founder populations, there is still some 60% of Icelandic familial breast cancer risk to be explained. This evidence concerns the gene BRCA1 and breast cancer.